Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Proteomic Characterisation of the Plasma Proteome in Extramedullary Multiple Myeloma Identifies Potential Prognostic Biomarkers

Katie Dunphy, Despina Bazou, Paul Dowling, Peter O'Gorman

Blood (2022) 140 (Supplement 1): 10058–10059.

https://doi.org/10.1182/blood-2022-159935

Published: 2022

Journal Articles

Targeted Metabolomics Approach Identifies Alterations in the Plasma Metabolome of Multiple Myeloma Patients with and without Extramedullary Spread

Katie Dunphy, Despina Bazou, Paul Dowling, Peter O'Gorman

Blood (2022) 140 (Supplement 1): 4328–4329.

https://doi.org/10.1182/blood-2022-160198

Published: 2022

Journal Articles

Phosphoproteomic Analysis of Primary Myeloma Patient Samples Identifies Distinct Phosphorylation Signatures Correlating with Chemo-Sensitivity Profiles in an Ex Vivo Drug Sensitivity Testing Platform

Katie Dunphy, Paul Dowling, Juho J. Miettinen, Caroline A. Heckman, Paula Meleady, Michael Henry, Despina Bazou, Peter O'Gorman

Blood (2021) 138 (Supplement 1): 2666.

https://doi.org/10.1182/blood-2021-148382

Published: 2021

Journal Articles

Characterisation of the Tumour Proteome in Primary Extramedullary Multiple Myeloma Identifies Key Proteins Associated with Transendothelial Migration

Katie Dunphy, Despina Bazou, Michael Henry, Paula Meleady, Paul Dowling, Peter O'Gorman

Blood (2021) 138 (Supplement 1): 2665.

https://doi.org/10.1182/blood-2021-152676

Published: 2021

Journal Articles

Saliva-Omics in Plasma Cell Disorders — Proof of Concept and Potential As a Non-Invasive Tool for Monitoring Disease Burden and MRD Status

Ciara Tierney, BSc, Despina Bazou, BSc, MSc, PhD, Giao Le, BA (Hons), MB BCh, MRCPI, Paul Dowling, BSc, PhD, Peter O'Gorman, MD PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 3177.

https://doi.org/10.1182/blood-2018-99-110166

Published: 2018

Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 264.

https://doi.org/10.1182/blood-2018-99-118242

Published: 2018

Journal Articles

Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing AllowsÂ Identification of Physiologically Distinct Sub-ClonesÂ That Can Inform Therapeutic and Drug Development Strategies

Despina Bazou, BSc, MSc, PhD, Muntasir M Majumder, MSc, BPharm, Ciara Tierney, BSc, Sinead O'Rourke, BSc, Pekka Anttila, MD, Raija Helena Silvennoinen, MD PhD, Caroline A Heckman, PhD, Paul Dowling, BSc, PhD, Peter O'Gorman, MD PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 1901.

https://doi.org/10.1182/blood-2018-99-115910

Published: 2018

Journal Articles

Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function

Matthew Ho, Jiye Liu, PhD, Alireza Kalbasi, PharmD, Takeshi Harada, MDPhD, Teru Hideshima, MD PhD, Paul Dowling, BSc, PhD, Yu-Tzu Tai, PhD, Li Zhang, MD, Kenneth Wen, BS, Ralph Mazitschek, Amanda McCann, Kenneth C Anderson, MD, Peter O'Gorman, MD PhD FRCP, FRCPath, Giada Bianchi, MD

Blood (2017) 130 (Supplement 1): 4429.

https://doi.org/10.1182/blood.V130.Suppl_1.4429.4429

Published: 2017

Journal Articles

Examining the Impact of Altered Protein Expression and Ubiquitination Levels on the Development of Resistance to Proteasome Inhibitors Using Proteomics Analysis

Paul Dowling, Kay Reen Ting, Justine Meiller, Shane Kelly, Martin Clynes, Peter O'Gorman

Blood (2015) 126 (23): 4208.

https://doi.org/10.1182/blood.V126.23.4208.4208

Published: 2015

Journal Articles

Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma

Kay Reen Ting, MB Bch BAO, Abdul Hameed, MBBS, MRCP, Jennifer Brady, Paul Dowling, PhD, Colin Clarke, PhD, Justine Meiller, Constantine S. Mitsiades, MD, PhD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Martin Clynes, PhD, Peter O'Gorman, MD, PhD

Blood (2013) 122 (21): 1869.

https://doi.org/10.1182/blood.V122.21.1869.1869

Published: 2013

Journal Articles

Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents

Catriona A. Hayes, MD, Paul Dowling, PhD, Richard W.J. Groen, PhD, Douglas W. McMillin, PhD, Jake E. Delmore, Hannah M. Jacobs, Niels W.C.J. van de Donk, MD, PhD, Eugen Dhimolea, PhD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Martin Clynes, PhD, Peter O'Gorman, M.D., Constantine S. Mitsiades, MD, PhD

Blood (2012) 120 (21): 3995.

https://doi.org/10.1182/blood.V120.21.3995.3995

Published: 2012

Journal Articles

Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance

*Catriona A. Hayes, MD, *Paul Dowling, PhD, Joseph Negri, Michael Henry, Leutz Buon, Jana Jakubikova, PhD, Jake E Delmore, Douglas W. McMillin, PhD, Steffen Klippel, PhD, Hannah M. Jacobs, Niels W.C.J. van de Donk, MD, PhD, Eugen Dhimolea, PhD, Panisinee Lawasut, MD, MSc, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Martin Clynes, PhD, *Peter O Gorman, MD, PhD, *Constantine S. Mitsiades, MD, PhD

Blood (2011) 118 (21): 1820.

https://doi.org/10.1182/blood.V118.21.1820.1820

Published: 2011

Journal Articles

Proteomics as a Functional Tool in Evaluating Bortezomib Treatment and Drug Resistance Mechanism.

Melissa G Ooi, M.D., Paul Dowling, Ph.D, Paul Richardson, M.D., Constantine S. Mitsiades, M.D., Ph.D, Martin Clynes, Ph.D, Kenneth C. Anderson, Peter O'Gorman, M.D.

Blood (2009) 114 (22): 1805.

https://doi.org/10.1182/blood.V114.22.1805.1805

Published: 2009

Journal Articles

A Panel of POTENTIAL PROTEIN BIOMARKERS for Predicting CLINICAL RESPONSE to Thalidomide IN Newly Diagnosed MULTIPLE MYELOMA PATIENTS.

Rajesh Rajpal, Paul Dowling, Justine Meiller, William G Murphy, Kenneth C. Anderson, MD, Philip Murphy, Robert O Connor, Martin Clynes, Peter O'Gorman, M.D.

Blood (2009) 114 (22): 4882.

https://doi.org/10.1182/blood.V114.22.4882.4882

Published: 2009

Journal Articles

Prediction of Thalidomide Response in the Newly Diagnosed Untreated Multiple Myeloma Patients Based on a Panel of Protein Biomarkers

Rajpal Rajpal, Paul Dowling, Justine Meiller, Kenneth C Anderson, MD, Philip Murphy, Martin Clynes, Peter O’Gorman

Blood (2008) 112 (11): 5018.

https://doi.org/10.1182/blood.V112.11.5018.5018

Published: 2008

NARROW

Proteomic Characterisation of the Plasma Proteome in Extramedullary Multiple Myeloma Identifies Potential Prognostic Biomarkers

Targeted Metabolomics Approach Identifies Alterations in the Plasma Metabolome of Multiple Myeloma Patients with and without Extramedullary Spread

Phosphoproteomic Analysis of Primary Myeloma Patient Samples Identifies Distinct Phosphorylation Signatures Correlating with Chemo-Sensitivity Profiles in an Ex Vivo Drug Sensitivity Testing Platform

Characterisation of the Tumour Proteome in Primary Extramedullary Multiple Myeloma Identifies Key Proteins Associated with Transendothelial Migration

Saliva-Omics in Plasma Cell Disorders — Proof of Concept and Potential As a Non-Invasive Tool for Monitoring Disease Burden and MRD Status

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing AllowsÂ Identification of Physiologically Distinct Sub-ClonesÂ That Can Inform Therapeutic and Drug Development Strategies

Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function

Examining the Impact of Altered Protein Expression and Ubiquitination Levels on the Development of Resistance to Proteasome Inhibitors Using Proteomics Analysis

Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma

Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents

Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance

Proteomics as a Functional Tool in Evaluating Bortezomib Treatment and Drug Resistance Mechanism.

A Panel of POTENTIAL PROTEIN BIOMARKERS for Predicting CLINICAL RESPONSE to Thalidomide IN Newly Diagnosed MULTIPLE MYELOMA PATIENTS.

Prediction of Thalidomide Response in the Newly Diagnosed Untreated Multiple Myeloma Patients Based on a Panel of Protein Biomarkers

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only